ANTENGENE-B (06996) announced its annual performance, with a adjusted net loss of 233 million yuan in the year, a year-on-year decrease of 23.50%.

date
16:35 20/03/2026
avatar
GMT Eight
Decky Pharmaceuticals-B (06996) announced its annual performance as of December 31, 2025. The group achieved a revenue of RMB 105 million, an increase of 14.56% year-on-year; research and development expenses were RMB 169 million, a decrease of 34.69% year-on-year; a loss of RMB 239 million was incurred during the year, a decrease of 25.10% year-on-year; after adjustment, the loss for the year was RMB 233 million, a decrease of 23.50% year-on-year; loss per share was 0.38 yuan.
ANTENGENE-B (06996) announced the annual performance ending on December 31, 2025. The group achieved a revenue of 105 million yuan (same unit), an increase of 14.56% year-on-year; research and development expenses were 169 million yuan, a decrease of 34.69% year-on-year; the net loss for the year was 239 million yuan, a decrease of 25.10% year-on-year; the adjusted net loss for the year was 233 million yuan, a decrease of 23.50% year-on-year; loss per share was 0.38 yuan. The announcement stated that the increase in revenue was mainly due to the accelerated contribution from the Chinese mainland, benefiting from the steady increase in market penetration rate and the deepening of commercial cooperation.